Abstract
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
Highlights
The ongoing coronavirus disease 2019 (COVID-19) is an extremely contagious and infectious viral illness induced by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) [1]
indicate that chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 was successfully isolated from egg yolks using the PEG precipitation method
The results of this study indicate that chicken egg yolk antibody (IgY) anti-RBD spike
Summary
The ongoing coronavirus disease 2019 (COVID-19) is an extremely contagious and infectious viral illness induced by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) [1]. The first cases of COVID-19 were announced on 31 December 2019 in Wuhan, China. COVID-19 has promptly developed into a global pandemic and become a substantial threat to international public health and the international economy [2,3]. 26 December 2021, the number of reported deaths due to COVID-19 is more than 5.3 million globally [4]. A number of prophylactic and therapeutic treatments are being developed and repurposed for COVID-19, including passive immunization, viral drugs, and vaccines [7,8,9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
